Results 101 to 110 of about 410,888 (293)
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Paying for Performance in Hospitals [PDF]
A frequent form of pay-for-performance programs increase reimbursement for all services by a certain percentage of the baseline price. We examine how such a ?bonus-for-quality?
Burkhard Hehenkamp, Oddvar Kaarbøe
core
Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims The aim of this study was to introduce a new assessment method for pharmacy students' real‐life competence in reviewing medications after obligatory advanced‐level practical internship in Finland. Methods The new medication review (MR) competence assessment method consisted of (1) a self‐assessment by pharmacy students and (2) a performance ...
Katja Leiman +5 more
wiley +1 more source
Regression Discontinuity Designs with an Endogenous Forcing Variable and an Application to Contracting in Health Care [PDF]
Regression discontinuity designs (RDDs) are a popular method to estimate treatment effects. However, RDDs may fail to yield consistent estimates if the forcing variable can be manipulated by the agent.
Han Hong +3 more
core
British Journal of Clinical Pharmacology, EarlyView.Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Prescribing cascades occur when medication is prescribed to prevent/treat the adverse effects of another medication and may be intentional/unintentional. This study examines the prevalence of nine prescribing cascades (ThinkCascades) in The Irish Longitudinal StuDy on Ageing (TILDA).
Ann Sinéad Doherty +7 more
wiley +1 more source
Using Cost Observation to Regulate Bureaucratic Firms [PDF]
We study regulation of a bureaucratic provider of a public good in the presence of moral hazard and adverse selection. By bureaucratic we mean that it values output in itself, and not only profit.
Ana Pinto Borges, João Correia-da-Silva
core
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Incentive Compatible Reimbursement Schemes for Physicians [PDF]
We consider physicians with fixed capacity levels. If a physician's capacity exceeds demand, she may have an incentive to overtreat, i.e., she may provide unnecessary treatments to use up idle capacity. By contrast, with excess demand she may undertreat,
Winand Emons
core